Program
ensifentrine
Also written as “Ensifentrine”, “RPL554” and “Ensifentrine 3 mg”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis · Asthma, led by 2 companies.
Drug pageEnsifentrine: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 152 open or running | phase 3since Aug 19, 2020 | Nov 30, 2014 | Mar 1, 2027phase 2 · NCT05270525 |
| Nuance Pharma (shanghai) | 20 open or running | phase 3since Feb 14, 2023 | Feb 14, 2023 | none ahead |
- Named in Merck’s own pipeline as
ensifentrine (+) glycopyrrolate (MK-5884A)
, phase 2, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Laboratory Corporation of America and Iqvia Pty.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseNuance Pharma licensed it from Verona Pharma, for Greater China (mainland China, Taiwan, Hong Kong and Macau).Agreed Jun 9, 2021 · Source: Verona Pharma (8-K), Jun 11, 2021
- AcquisitionMerck acquired Verona Pharma, and with it ensifentrine (Ohtuvayre).Completed Oct 7, 2025 · Source: Merck, Oct 7, 2025
History and studies of Nuance Pharma (shanghai) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named ensifentrineINNProposed as its International Nonproprietary Name in WHO's List 119 · before, RPL554
- Jun 9, 2021Nuance Pharma licensed it from Verona PharmaLicenseGreater China (mainland China, Taiwan, Hong Kong and Macau) · agreed · Verona Pharma (8-K)
- Feb 14, 2023First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05758428 · 28 enrolled · China
- Feb 14, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT05743075 · 526 enrolled · China
- Oct 7, 2025Merck acquired Verona PharmaAcquisitionWith it ensifentrine (Ohtuvayre) · completed · Merck
TargetBeta
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-…”NCIt, read by Claude
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), ”NCIt, by rule
“Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor”ChEMBL 37, by rule
Studies
All 2 Nuance Pharma (shanghai) leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05758428Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Apr 18, 2023 | 28 |
| NCT05743075Pulmonary Disease, Chronic Obstructive · China | 3 | Completed | Dec 6, 2024 | 526 |
How it is read
Names in the registry
- “Ensifentrine”, 7 entries
- “RPL554”, 4 entries
- “Ensifentrine 3 mg”, 2 entries
- “Ensifentrine 1.5 mg”, 1 entry
- “Ensifentrine 3 mg (marketed formulation)”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 15 studies
- Cystic Fibrosis, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.